LTM Q1 FY27: Top line at Rs 11,608 crore, operationally strong show—Key takeaways for investors

​ITR Filing 2026: Penalties, refund delays and consequences of not filing Income Tax Return

Big BIS update! These 4 Indian Standards have changed; check the full list

EPFO Amnesty Scheme 2026 explained: Eligibility, key benefits, deadline and all you need to know

US launches 3rd round of strikes on Iran after alleged attack on commercial ship, says CENTCOM

Ashwini Vaishnaw outlines big AI roadmap for Viksit Bharat 2047, promises stronger compute capacity

Singapore Real Estate: 3 reasons why Indian investors still choose this market despite 60% ABSD

DMart Q1 FY27 Results: At Rs 936 crore, PAT beats estimates; margin in line—Key takeaways

IPOs Next Week: Rs 11,693 crore SBI MF IPO, Alpine Texworld issue to open; key allotments and listings ahead

Trump's big warning to Iran: Claims '1,000 missiles' ready if Iran tries to assassinate him

Analysts at Jefferies believe injunction is a negative surprise for Dr Reddy’s and risks for FY20-22 EPS estimates have increased after the ruling. retain “underperform”, cuts TP to 1,850 rupees from 1,910 rupees

Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%

S&amp;P500 mini futures&nbsp;fell as much as 0.5 per cent in early trade while MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.2 per cent. Japan's Nikkeilost 0.4 percent.&nbsp;

FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas

Dr Reddy's share price gained as much as 20 per cent in the last 8 sessions, thanks to a renewed optimism on the sector. Nifty Pharma index itself gained 14 per cent during the same period. In Friday's trade, Nifty Pharma was the top sectoral gainer, led by gains in Dr Reddy's.&nbsp;

Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions

In pre-market opening, the 31-scrip index was trading lower at 32,406-level and that of 51-scrip index was below 10,140-mark.&nbsp;

Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike 

GV Prasad, Co-Chairman and CEO of Dr Reddy's Laboratories said, “FY17 has been challenging year due to lack of new product approvals for the US market. However, our other geoghraphies delivered good performance with several new product launches.”

 Dr Reddy's Q4 net profit rises by 319% 

In Q3FY17, the company reported consolidated net profit of Rs 492.3 crore, down&nbsp;15.94% year-on-year compared to Rs 585.7 crore in the corresponding period of the previous year.

Dr Reddy's Laboratories Q4 review: Here's what to expect

According to experts, the stock markets this week will be guided by the fourth quarter (Q4) corporate earnings, macroeconomic data and French elections results.

Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week

GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&amp;A cost across all our business."

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

USFDA to re-audit Dr Reddy's three plants in first quarter of 2017 

The global generics sector saw a significant de-rating in YTD (year-to-date) in the&nbsp; CY2016 with 1-year forward P/E (price over equity)&nbsp; contracting by 34%, with the past one month itself witnessing an 11%.

What would a Hillary Clinton win mean for Indian Pharma?

Media reports suggest that&nbsp;the US Congress investigation into price hikes, that began in October 2014, may be nearing completion, culminating into charges of price collusion against companies / individuals by the year end.&nbsp;

Pharma stocks fall sharply as US drug pricing investigation nears completion

Inter-ministerial body FIPB will this week take up 19 foreign investment proposals, including those of Dr Reddy's Laboratories and JC Decaux Advertising.

FIPB to take up 19 investment proposals this week

Dr Reddy's introduces Aripiprazole, USP tablets in US market; stock down 1.04% 

G V Prasad, Co-chairman and CEO of Dr Reddy's Laboratories said,” This listing has earned us the trust and respect of all stakeholders we serve. I see our inclusion in the Dow Jones indices as another validation of our commitment to sustainability in all aspects of our business.”

Dr Reddy gets listed on Dow Jones sustainability indices 2016

Domestic pharma players are in&nbsp;stiff competition in US market. Sun Pharma with its taking over of SPARC's&nbsp;ELEPSIA XR, while Dr. Reddy launching&nbsp;Omeprazole and Sodium bicarbonate capsules and that of Glenmark waiting for 62 ANDA's approval, plans to strenghthen their position in the US.&nbsp;

Sun, Dr Reddy's, Glenmark strengthen their US play

"Brexit has raised business concerns around the world about trade and currency fluctuations, but Indian pharma seems immune," Surya Patra and Mehul Sheth from Phillip Capital Research said in research note on June 24.&nbsp;

Brexit impact: Indian pharma seems immune, says Phillip Capital 

The company has a strong track record in the US market with over 79 filed ANDAs pending approval, of which we believe 18 have first-to-file status.

Dr Reddy's to buy eight ANDAs in US for Rs 2,300 crore

dr-reddys-laboratories-0










Dr Reddy’s Laboratories reported a steep decline in fourth-quarter profit after exceptional charges linked to lenalidomide and asset impairments impacted earnings, but the pharma major still announced an 800 per cent final dividend payout for FY26.




 

 




 


 

Dr Reddy’s Q4 Results: Pharma major declares 800% dividend despite 86% plunge in profit to Rs 220 crore

Should you buy, sell or hold Dr Reddy's Labs shares? Here's what brokerages suggest

Zee Business Research Team expects steady revenue growth and moderate profit gains, with US pricing pressure and Revlimid erosion weighing on overall performance.

Dr Reddy’s Q2 Results Preview: Muted quarter likely; Revlimid drag may offset India gains

The Hyderabad-based drug major Dr Reddy's Laboratories had reported a profit of Rs 1,379 crore for the October-December period of last fiscal.

Dr Reddy's Q3 FY25 Results: Drug major's profit up 2% at Rs 1,413 crore

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary.

Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority

Zee Business

Home

Personal Finance

India

Economy

Tech

Auto

Markets

Jobs

Indian Railways

World

Videos

Photos

Dr Reddy's Laboratories News- Zee Business provides latest news on Dr Reddy's Laboratories, Dr Reddy's Laboratories news Today, Top News on Dr Reddy's Laboratories, update on Dr Reddy's Laboratories Stay updated with business news, breaking news headlines.

Dr Reddy's Laboratories Latest News- Top News on Dr Reddy's Laboratories, Update on Dr Reddy's Laboratories, Dr Reddy's Laboratories News Today, Breaking News Headlines, Business News | Zee Business

Dr Reddy's Laboratories

Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%

FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas

Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions

Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike

Dr Reddy's Q4 net profit rises by 319%

Dr Reddy's Laboratories Q4 review: Here's what to expect

RECOMMENDED

LTM Q1 FY27: Top line at Rs 11,608 crore, operationally strong show—Key takeaways for investors

​ITR Filing 2026: Penalties, refund delays and consequences of not filing Income Tax Return

Big BIS update! These 4 Indian Standards have changed; check the full list

EPFO Amnesty Scheme 2026 explained: Eligibility, key benefits, deadline and all you need to know

US launches 3rd round of strikes on Iran after alleged attack on commercial ship, says CENTCOM

Ashwini Vaishnaw outlines big AI roadmap for Viksit Bharat 2047, promises stronger compute capacity

Singapore Real Estate: 3 reasons why Indian investors still choose this market despite 60% ABSD

DMart Q1 FY27 Results: At Rs 936 crore, PAT beats estimates; margin in line—Key takeaways

IPOs Next Week: Rs 11,693 crore SBI MF IPO, Alpine Texworld issue to open; key allotments and listings ahead

Trump's big warning to Iran: Claims '1,000 missiles' ready if Iran tries to assassinate him

Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

USFDA to re-audit Dr Reddy's three plants in first quarter of 2017

What would a Hillary Clinton win mean for Indian Pharma?

Pharma stocks fall sharply as US drug pricing investigation nears completion

FIPB to take up 19 investment proposals this week

Dr Reddy's introduces Aripiprazole, USP tablets in US market; stock down 1.04%

Dr Reddy gets listed on Dow Jones sustainability indices 2016

Sun, Dr Reddy's, Glenmark strengthen their US play

Brexit impact: Indian pharma seems immune, says Phillip Capital

Dr Reddy's to buy eight ANDAs in US for Rs 2,300 crore

Top News

LTM Q1 FY27: Top line at Rs 11,608 crore, operationally strong show—Key takeaways for investors

​ITR Filing 2026: Penalties, refund delays and consequences of not filing Income Tax Return

Big BIS update! These 4 Indian Standards have changed; check the full list

EPFO Amnesty Scheme 2026 explained: Eligibility, key benefits, deadline and all you need to know

US launches 3rd round of strikes on Iran after alleged attack on commercial ship, says CENTCOM

Ashwini Vaishnaw outlines big AI roadmap for Viksit Bharat 2047, promises stronger compute capacity

ITR Filing 2026: Penalties, refund delays and consequences of not filing Income Tax Return

ITR Filing 2026: Penalties, refund delays and consequences of not filing Income Tax Return